Violi F, Hiatt W
Department of Experimental Medicine, University of Rome La Sapienza, Rome, Italy.
Intern Emerg Med. 2007 Jun;2(2):84-7. doi: 10.1007/s11739-007-0040-z. Epub 2007 Jul 18.
Peripheral arterial disease (PAD) is a clinical setting affecting more than 5% of the population older than 60. Despite the low rate of peripheral complications and amputation, PAD is complicated by a high rate of coronary and cerebral events. For this reason, PAD is considered a marker for systemic atherosclerosis and its early diagnosis may be helpful for identifying patients at risk for cardiovascular events. During these last years, many clinical trials with antiplatelet drugs have been conducted to assess if these medications are able to influence the clinical history of PAD. This review will analyse the strengths and drawbacks of these clinical trials and their impact on clinical practice.
外周动脉疾病（PAD）是一种临床病症，影响着超过5%的60岁以上人群。尽管外周并发症和截肢发生率较低，但PAD常并发高发生率的冠状动脉和脑血管事件。因此，PAD被视为全身动脉粥样硬化的一个标志，其早期诊断可能有助于识别有心血管事件风险的患者。在过去几年中，已经开展了许多使用抗血小板药物的临床试验，以评估这些药物是否能够影响PAD的临床病程。本综述将分析这些临床试验的优缺点及其对临床实践的影响。
